Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus ULTRATAG.
HIPPURAN I 131 vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
NOT FOUND
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical